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Abstract
IMPORTANCE—Annually in the United States, at least 3.5 million people seek medical attention 
for traumatic brain injury (TBI). The development of therapies for TBI is limited by the absence of 
diagnostic and prognostic biomarkers. Microtubule-associated protein tau is an axonal 
phosphoprotein. To date, the presence of the hypophosphorylated tau protein (P-tau) in plasma 
from patients with acute TBI and chronic TBI has not been investigated.
OBJECTIVE—To examine the associations between plasma P-tau and total-tau (T-tau) levels and 
injury presence, severity, type of pathoanatomic lesion (neuroimaging), and patient outcomes in 
acute and chronic TBI.
DESIGN, SETTING, AND PARTICIPANTS—In the TRACK-TBI Pilot study, plasma was 
collected at a single time point from 196 patients with acute TBI admitted to 3 level I trauma 
centers (<24 hours after injury) and 21 patients with TBI admitted to inpatient rehabilitation units 
(mean [SD], 176.4 [44.5] days after injury). Control samples were purchased from a commercial 
vendor. The TRACK-TBI Pilot study was conducted from April 1, 2010, to June 30, 2012. Data 
analysis for the current investigation was performed from August 1, 2015, to March 13, 2017.
MAIN OUTCOMES AND MEASURES—Plasma samples were assayed for P-tau (using an 
antibody that specifically recognizes phosphothreonine-231) and T-tau using ultra-high sensitivity 
laser-based immunoassay multi-arrayed fiberoptics conjugated with rolling circle amplification.
RESULTS—In the 217 patients with TBI, 161 (74.2%) were men; mean (SD) age was 42.5 (18.1) 
years. The P-tau and T-tau levels and P-tau–T-tau ratio in patients with acute TBI were higher than 
those in healthy controls. Receiver operating characteristic analysis for the 3 tau indices 
demonstrated accuracy with area under the curve (AUC) of 1.000, 0.916, and 1.000, respectively, 
for discriminating mild TBI (Glasgow Coma Scale [GCS] score, 13–15, n = 162) from healthy 
controls. The P-tau level and P-tau–T-tau ratio were higher in individuals with more severe TBI 
(GCS, ≤12 vs 13–15). The P-tau level and P-tau–T-tau ratio outperformed the T-tau level in 
distinguishing cranial computed tomography–positive from −negative cases (AUC = 0.921, 0.923, 
and 0.646, respectively). Acute P-tau levels and P-tau–T-tau ratio weakly distinguished patients 
with TBI who had good outcomes (Glasgow Outcome Scale–Extended GOS-E, 7–8) (AUC = 
0.663 and 0.658, respectively) and identified those with poor outcomes (GOS-E, ≤4 vs >4) (AUC 
= 0.771 and 0.777, respectively). Plasma samples from patients with chronic TBI also showed 
elevated P-tau levels and a P-tau–T-tau ratio significantly higher than that of healthy controls, with 
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both P-tau indices strongly discriminating patients with chronic TBI from healthy controls (AUC = 
1.000 and 0.963, respectively).
CONCLUSIONS AND RELEVANCE—Plasma P-tau levels and P-tau–T-tau ratio outperformed 
T-tau level as diagnostic and prognostic biomarkers for acute TBI. Compared with T-tau levels 
alone, P-tau levels and P-tau–T-tau ratios show more robust and sustained elevations among 
patients with chronic TBI.
Traumatic brain injury(TBI), considered as an event and/or a disease, initiates a complex 
pathophysiologic central nervous system cascade with acute effects and secondary insults 
that may lead to chronic functional, neurocognitive, and neuropsychiatric deficits.1 
Traumatic brain injury is classified according to its degree of severity (mild, moderate, and 
severe). In the United States, there are more than 3.5 million emergency department visits 
for TBI and more than 280000 patients are hospitalized annually with TBI, with most of 
these classified as mild TBI (mTBI). There are also many more individuals with mTBI who 
never seek medical attention. More than 300000 armed service members sustained TBI 
during combat and training from 2000 to 2014.2 Approximately half of patients with TBI in 
the United States incur at least some short-term disability.3 Traumatic brain injury is 
associated with an increased risk of neurodegenerative disorders, such as Alzheimer disease, 
years or decades after injury.4 In addition, repetitive mTBI is a risk factor for a 
neurodegenerative condition called chronic traumatic encephalopathy(CTE).5–7 Chronic 
traumatic encephalopathy, which can be confirmed only by postmortem neuropathologic 
examination, is defined by the abnormal accumulation of hyperphosphorylated tau protein 
(P-tau) in neurons, astroglia, and cell processes distributed around small blood vessels at the 
depth of cortical sulci in an irregular pattern.8
Tau protein is involved in regulating axonal microtubule assembly and disassembly. 
Posttranslational modifications of tau seem to precede brain tauopathy. These modifications 
include (1) hyperphosphorylation by multiple kinases,9 (2) proteolysis by 
calpainandcaspase,10–12 and (3) oxidative modifications.13–15 The abnormal P-tau protein 
forms paired helical filaments and progressively aggregates to form the main component of 
neurofibrillary tangles—a hallmark of tauopathy, including Alzheimer disease.16 The major 
pathologic P-tau sites include, but are not limited to, threonine (Thr)181, serine (Ser)202, 
Thr205, Thr231, Ser396, and Ser404.17 Abnormal accumulation of P-tau deposits in 
postmortem human brains are found years after repetitive mTBIs have been sustained.18,19 
Single, simulated blast exposure and closed head injury in mice also result in increased 
deposition of P-tau.20,21 Amyloid β1–42 and/or tau levels are elevated in cerebrospinal fluid 
samples after severe TBI.22–24 The use of a high-sensitivity assay platform 
(Simoa;Quanterix Corp) has permitted detection of acute and chronic tau elevations 
following mTBI in ice hockey players with sports-related concussion and military personnel 
with chronic postconcussive disorder symptoms.25,26 In contrast to the present report, those 
studies did not measure P-tau levels.
We recently used another high-sensitivity assay platform (multi-arrayed fiberoptics 
conjugated with rolling circle amplification [a-EIMAF]) and detected serumtotal (T)-tau and 
P-tau levels in patients with severe TBI,27 as well as in 1- to 30-day mouse serum after 
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single and/or repetitive mTBI.21 However, to our knowledge, the profile of P-tau in blood 
samples in humans with mild and moderate TBI has yet to be defined. Incorporating the 3 
tau indices to distinguish abnormal cranial computed tomography (CT) (pathoanatomic 
lesions) from normal CT findings would aid in the diagnosis and prognosis for acute TBI. 
Furthermore, to our knowledge, monitoring the 3 tau indices simultaneously in blood 
samples from patients with chronic TBI has not been done previously. Therefore, we used 
the a-EIMAF platform to examine whether P-tau and T-tau might be sensitive and specific 
biomarkers, using plasma from patient cohorts in the completed TRACK-TBI Pilot study.
Methods
TBI Patients and Biosample Collection
Four sites (3 level I trauma centers and 1 rehabilitation center) participated in this study. On 
arrival, participants were classified along the spectrum of neurotrauma severity (Glasgow 
Coma Scale [GCS)] score of 3–8, severe; 9–12, moderate; and 13–15, mild) and recruited 
into the multicenter, prospective TRACK-TBI Pilot study.28 The TRACK-TBI Pilot study 
was conducted from April 1, 2010, to June 30, 2012. Data analysis for the current 
investigation was performed from August 1, 2015, to March 13, 2017.
Study protocols were approved by the institutional review boards of participating centers 
(acute sites: San Francisco General Hospital, San Francisco, California; University of 
Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and University Medical Center 
Brackenridge, Austin, Texas; rehabilitation site: Mount Sinai Rehabilitation Center, New 
York). Participants or their legally authorized representative provided written informed 
consent.
Patients with acute TBI must have presented within 24 hours of injury to the emergency 
department and have had a noncontrast head CT scan performed based on American College 
of Emergency Physicians/Centers for Disease Control and Prevention guidelines29; patients 
with chronic TBI must have had sufficient neurologic impairment to be admitted to inpatient 
TBI rehabilitation units.30 Single blood samples from patients with acute TBI across the full 
spectrum of injury severity( GCS, 3–8 [n = 25]); GCS, 9–12 [n = 8]; and GCS, 13–15 [n = 
163]) were collected within 24 hours of injury. Among these patients with acute TBI, 108 
(55.1%) had normal head CT (CT−) scans, while 88 (44.9%) showed CT abnormality (CT+) 
(Table). Single blood samples from 21 patients with chronic TBI were collected during the 
inpatient rehabilitation stay (Table).30 Sample collection and processing for the TBI and 
healthy control cohorts were performed identically at all sites (including the commercial 
vendor for controls) according to the recommendations from the National Institutes of 
Health–National Institute of Neurological Disorders and Stroke Common Data Elements 
Biospecimens and Biomarkers Working Group31 (eMethods in the Supplement provides 
details). Plasma was extracted after centrifugation of whole blood collected in K2-EDTA 
blood tubes for 5 minutes at 3000g. In addition, 20 commercially obtained samples 
(Bioreclamation Inc) from healthy control plasma (K2-EDTA tubes) (n = 20; mean [SD] 
age, 40.5 [14.2] years; 70% male), which were sex-and age-matched with the acute (n = 196; 
age, 42.1 [18.1] years; 73% male) and chronic (n = 21; age, 44.4 [20.5] years; 76% male) 
TBI samples, were assayed. There were no significant differences in age or sex across the 
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patient and control cohorts (Table). In the 217 patients with TBI, 161 (74.2%) were men; 
mean age was 42.5 (18.1) years.
Plasma P-tau and T-tau Analysis by a-EIMAF
T-tau and P-tau a-EIMAF assay performance, lower limit of detection, lower limit of 
quantitation, and linearity range of standard curves for calculating T-tau and P-tau 
concentration are shown in eFigures 1 and 2 in the Supplement, respectively (eMethods in 
the Supplement).
Statistical Analysis
The T-tau and P-tau data for the acute and chronic TBI cohorts and controls were not 
normally distributed; thus, results are presented as median and interquartile range. Median 
differences for more than 2 groups were compared with the Kruskal-Wallis test. For 2-group 
comparisons, the non-parametric Mann-Whitney test was performed. The ability of T-tau 
level, P-tau level, and P-tau–T-tau ratio to distinguish patients with acute TBI vs controls, 
mild(GCS, 13–15) vs moderate/severe (GCS, 3–12) TBI, normal vs abnormal cranial CT, 6-
month outcomes on Glasgow Outcome Scale–Extended (GOS-E), and chronic TBI vs 
controls were assessed using the receiver operating characteristic (ROC) curve and 
associated area under the curve (AUC). Statistical analyses were performed using Prism, 
version 6 (GraphPad Software). Statistical significance was defined by an unpaired, 2-tailed 
P value ≤.05.
Results
Plasma P-tau levels, T-tau levels, and P-tau–T-tau ratios were determined for all patients 
with acute and chronic TBI. We have previously described detection of T-tau and P-tau in 
cerebrospinal fluid (EIMAF format) and serum(a-EIMAF format) from patients with severe 
TBI during the first 5 days after injury.28 Herein, we expand these findings by using plasma 
samples from 2 cohorts of the TRACK-TBI Pilot study and quantitate concentrations of T-
tau and P-tau (eFigure 1 and eFigure 2 in the Supplement).
In controls, we found no significant correlations between any of the 3 tau indices and age. 
For CT− patients, age had statistically significant Pearson correlation coefficients with P-tau 
level (r = 0.200, P = .04) and P-tau–T-tau ratio (r = 0.233, P = .02), but not with T-tau level (r 
= −0.075, P = .45). For CT+ patients, age had a statistically significant Pearson correlation 
coefficient with P-tau–T-tau ratio (r = 0.219, P = .04), but not for P-tau (r = 0.157, P = .14) 
or T-tau (r = −0.082, P = .44) levels.
T-tau and P-tau Levels in TBI of Different Severities vs Controls
Plasma values of T-tau were 62.59 fg/mL for healthy controls, 79.21 fg/mL for patients with 
acute TBI with initial GCS 13 to 15, 84.10 fg/mL for GCS 9 to 12, and 79.21 for GCS 3 to 8 
(P < .001 across groups) (Figure 1A, eTable 1 in the Supplement). Median P-tau level was 
20.85 fg/mL × 100 for healthy controls, 200.16 fg/mL × 100 for patients with acute TBI 
with GCS 13 to 15, 307.19 fg/mL × 100 for GCS 9 to 12, and 294.68 fg/mL × 100 for GCS 
3 to 8 (P < .001) (Figure 1A, eTable 1 in the Supplement). P-tau–T-tau ratio ( × 10 000) for 
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healthy controls was 30.94, compared with 263.19 for patients with acute TBI with GCS 13 
to 15, 348.38 for GCS 9 to 12, and 363.02 for GCS 3 to 8 (P < .001) (Figure 1A, eTable 1 in 
the Supplement). Healthy controls compared with each severity group were significantly 
different for T-tau level, P-tau level, and P-tau–T-tau ratio (eTable 2 in the Supplement). P-
tau values for GCS 13 to 15 vs GCS 9 to 12 and GCS 13 to 15 vs GCS 3 to 8 were 
significantly different, as were P-tau–T-tau ratios for GCS 13 to 15 vs GCS 3 to 8 (eTable 2 
in the Supplement).
The ROC analyses showed the accuracy of all 3 plasma tau indices in distinguishing all 
acute TBI cases from healthy controls (Figure 1B). The AUC was 0.919 (P < .001) for T-tau 
level, 1.000(P < .001) for P-tau level, and 1.000(P < .001) for P-tau–T-tau ratio (eTable 3 in 
the Supplement, all TBI vs controls). All 3 plasma tau indices also showed accuracy in 
distinguishing mTBI (GCS 13–15) from normal control plasma (Figure 1C), with AUC = 
0.916 (P < .001) for T-tau level, 1.000(P < .001) for P-tau level, and 1.000 (P < .001) for P-
tau–T-tau (eTable 3 in the Supplement, mTBI vs controls).
Because our results suggested that P-tau indices could distinguish mTBI (GCS 13–15) from 
severe and moderate TBI (eTable 2 in the Supplement), we further applied ROC plots 
(Figure 1D). Plasma P-tau levels and P-tau–T-tau ratio showed fair accuracy for 
distinguishing mTBI (initial GCS 13–15) in patients with severe/moderate TBI (GCS≤12) 
(AUC = 0.711 and 0.748, respectively; both P < .001), whereas T-tau showed poor, but 
significant results (AUC 0.527, P = .04) (Figure 1D; eTable 4 in the Supplement).
Pathoanatomic Lesion Correlation
Neuroimaging using CT assessed the extent of the TBI, thereby allowing pathoanatomic 
classification. We assessed the ability of the 3 plasma tau indices to distinguish CT+ scan 
patients with TBI from those with normal findings on scans (CT−). As displayed in Figure 
2A–C, median T-tau levels were 78.24 fg/mL for CT− and 83.13 fg/mL for CT+ scans (P < .
001) (Figure 2A). P-tau levels were 1.45 fg/mL for CT− and 3.02 fg/mL for CT+ scans (P 
< .001) (Figure 2B), and the P-tau–T-tau ratio had a median of 0.0187 for CT− and 0.0363 
for CT+ scans (P < .001) (Figure 2C). We also performed ROC analysis of 3 tau indices in 
distinguishing CT+ from CT− scans (Figure 2D). Both P-tau level and P-tau–T-tau ratio had 
excellent accuracy (AUC = 0.921 and 0.923, respectively), while T-tau had poor accuracy 
(AUC = 0.646) (eTable 5 in the Supplement).
We compared the acute TBI tau indices of the mTBI (GCS 13–15) groups that had scans that 
were either CT+(n = 61) or CT− (n = 102) with those of healthy controls (n = 20) (eFigure 3 
in the Supplement). We identified significant group differences for T-tau level, P-tau level, 
and P-tau–T-tau ratio. Healthy controls could be distinguished from both CT+ and CT− 
cases based on all 3 tau indices (eFigure 3 in the Supplement). Furthermore, P-tau levels and 
P-tau–T-tau ratio could distinguish CT+ vs CT− scans among all patients with mTBI, 
although T-tau levels could not (eFigure 3 in the Supplement).
Finally, we investigated the correlation between acute TBI plasma tau indices and the 
Marshall CT scale. Owing to small individual counts, the more severe Marshall CT 
classifications (3–6) were grouped into a single category similar to previous 
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approaches.32–34 Marshall group comparisons showed statistical significance for all 3 tau 
indices (all P < .001) (eFigure 4 in the Supplement). We also found significant subgroup 
differences in Marshall CT scores: (1) T-tau level, 1 vs 2 (P < .001) and 1 vs 3 or higher (P 
< .05); (2) P-tau level, 1 vs 2 (P < .001) and 1 vs 3 or higher (P < .001); and P-tau–T-tau 
ratio, 1 vs 2 (P < .001) and 1 vs 3 or higher (P < .001) (eFigure 4 in the Supplement).
Outcome Correlation
Since P-tau might be related to tauopathy formation, we examined the ability of the plasma 
tau indices to predict outcome in patients with TBI using the GOS-E. Six-month outcome 
data were available in 137 patients (69.9%), 134 of whom had available plasma samples 
(68.3%) (Table). A GOS-E score of 7 to 8 is considered a good outcome, and a GOS-E score 
of 6 or lower is considered a poor outcome. Figure 3B and C demonstrate that both acute 
TBI plasma P-tau level and P-tau–T-tau ratio have an inverse association with GOS-E. P-tau 
level (P = .001) and P-tau–T-tau ratio (P = .002) are lower in patients with TBI with a GOS-
E of 7 to 8 vs those with a GOS-E of 6 or lower. In contrast, T-tau did not differ significantly 
between the 2 outcome groups (P = .27) (Figure 3A). In the good outcome (GOS-E, 7–8) 
column for P-tau level and P-tau–T-tau ratio, there appear to be 2 clusters (above or below 2 
fg/mL P-tau level; and above or below 0.025 P-tau–T-tau ratio, respectively). These upper 
clusters closely match the respective ranges of P-tau level and P-tau–T-tau ratio for the poor 
outcome group (GOS-E, ≤6). This finding may suggest a natural clustering of acute post-
TBI P-tau levels that are independent of our patient outcome measures (eg, GOS-E). In ROC 
curves for GOS-E of 7 to 8 (good outcome) vs GOS-E of 6 or lower (Figure 3D), the AUC 
for P-tau level (0.663) and P-tau–T-tau ratio (0.658) show that they are poor predictors of 
good outcome (eTable 6 in the Supplement, panel A). T-tau level failed to discriminate 
between those with good outcome (AUC = 0.552). In ROC curves for GOS-E of 4 or lower 
(poor outcome) vs GOS-E higher than 4 (Figure 3E), AUC for P-tau level (0.771) and for P-
tau–T-tau ratio (0.777) shows that both of these P-tau indices are fair predictors of poor 
outcome (eTable 6 in the Supplement, panel B). The AUC for T-tau level (0.516) was again 
not significant.
Characterization of Plasma Tau Indices in Patients With Chronic TBI
For the chronic TBI cohort, the mean (SD) postinjury time at enrollment was 176.4 (44.5) 
days (range, 16.0–249.6 days). The plasma T-tau level, P-tau level, and P-tau–T-tau ratio 
were compared with those of healthy controls (n = 20) (Figure 4A). Median plasma T-tau 
level for chronic TBI was 69.48 vs 62.59 fg/mL for controls (P = .02); P-tau level was 97.30 
fg/mL × 100 for chronic TBI vs 20.85 fg/mL × 100 for controls (P < .001); and the P-tau–T-
tau ratio ( × 10000) was 140.33 for chronic TBI vs 30.95 for controls (P < .001).
Finally, we performed ROC curves of plasma T-tau level, P-tau level, and P-tau–T-tau ratio 
from patients with chronic TBI vs healthy controls (Figure 4B). P-tau level (AUC = 1.000) 
and P-tau–T-tau ratio (AUC = 0.963) showed accuracy and outperformed T-tau level (AUC = 
0.674) (eTable 7 in the Supplement).
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Discussion
Biomarkers are emerging diagnostic tools for TBI. Since P-tau is pathologically linked to 
tauopathy found in Alzheimer disease, CTE, and other neurodegenerative diseases 
associated with TBI,7,18,20 we examined peripheral T-tau and P-tau levels in the full 
spectrum of patients with TBI by using TRACK-TBI Pilot cohorts.28,30,35 We demonstrate 
that plasma P-tau (P-Thr231) level, T-tau level, and P-tau–T-tau ratio are robustly higher in 
patients with all severities of acute TBI compared with healthy controls (Figure 1A). 
However, both P-tau indices differed according to TBI severity (Figure 1D). Although all 
patients with TBI and cranial CT+ scans had higher levels of all 3 tau indices than their CT− 
counterparts, P-tau levels and P-tau–T-tau ratio were much higher and predicted CT scan 
abnormality more accurately than did T-tau levels (Figure 2). In patients with acute TBI, P-
tau levels and P-tau–T-tau ratio outperformed T-tau level in identifying and possibly 
predicting good outcomes (Figure 3). Taken together, to our knowledge, this is the first 
report showing that acute plasma P-tau levels and the P-tau–T-tau ratio are superior 
diagnostic biomarkers for TBI than T-tau levels. Because of the likely differences in T-tau 
antigen standards and antibodies used in the different assay formats, making direct 
comparisons between the absolute plasma T-tau values from the acute mild and chronic TBI 
cohorts reported in our study with the previous reports on concussed ice-hockey players25 
and military personnel26 is not possible.
Recent studies35–37 have examined the use of blood biomarkers, which included ubiquitin C-
terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), for the diagnosis 
and prognosis of TBI. Each of these biomarkers was effective alone and, in 1 study,35 more 
specific and sensitive when combined in diagnosing TBI. However, a potential limitation of 
these studies is the short half-lives of UCH-L1 (<12 hours) and GFAP (<2 days) combined 
with the sensitivity limits of currently available assays.36,38 P-tau and T-tau levels in 
cerebrospinal fluid have diagnostic value for identifying individuals with Alzheimer 
disease.39–41 However, detection of these proteins in blood have been challenging owing to 
their low levels, which may now be overcome by the availability of new high-sensitivity 
assay platforms (single molecule array and a-EIMAF).25–27
We also found that plasma P-tau levels and P-tau–T-tau ratio in patients with chronic TBI are 
significantly higher than in healthy controls (Figure 4). Chronic traumatic encephalopathy 
was first described in 1928 by Martland42 to describe the clinical tremors and impaired 
cognition that affected some boxers. Being “punch drunk” was later called “dementia 
pugilistica”7 and then refined as CTE.43,44 Patients with CTE show progressively worsening 
dementia, poor executive function, confusion, anxiety, depression, and irritability that appear 
years after the initial trauma events.45,46 Omalu and colleagues5,19 reported neuropathologic 
lesions consistent with CTE in the brain of an American football player and a professional 
wrestler. Although CTE is associated with a history of repetitive mTBI or concussion, it is 
possible that a single but significant TBI event could also lead to the initiation of a tau 
phosphorylation cascade similar to those observed in repetitive mTBI. Consistent with this, 
our study showed elevations of plasma P-tau and T-tau levels in both the acute and the 
chronic phases of TBI. If, infact, the tau phosphorylation cascade extends from the acute 
post-TBI phase into the chronic phase, it is possible that, in vulnerable individuals or those 
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who experience successive TBI events, there may be sufficient cumulative tauopathy to 
initiate and/or accelerate the development of CTE.
For detection of tauopathy in particularly vulnerable TBI cohorts (athletes and blast-exposed 
military), postmortem neuropathologic examination along with blood T-tau and P-tau level 
quantitation is ideal; however, conducting both is often infeasible. The development of 
specific tau tracers for positron emission tomographic imaging have enabled the analysis of 
the presence and intensity of tau pathology in patients suspected of having tauopathies.47 
Thus, future studies correlating tau positron emission tomographic imaging data with the 
levels of P-tau and P-tau–T-tau ratios may offer a novel path for differential diagnosis, 
prognosis, and disease progression in patients with TBI.5,6,19
Limitations
The fact that control samples were not collected at the study sites is a major limitation of the 
study. These commercially obtained control plasma samples had limited demographic and 
health status data of donors. Although all control and TBI patient samples collected for this 
study followed best practice guidelines, it is possible that the reliance on commercial control 
samples may have affected the comparisons between controls and patients with TBI due to 
possible differences in sample collection and processing. To address this limitation, we will 
further validate our T-tau and P-tau results using blood samples collected within 24 hours, at 
1 to 2 weeks, and at 6 months after the TBI from approximately 1000 patients with TBI in 
the current TRACK-TBI study48 supplemented with 2 groups of controls: friends/family 
controls (n = 300) and non-TBI orthopedic injury controls (n = 300).36,49 Thus far, we were 
able to successfully contact and recruit a friend or family member for 92% of the case 
patients. This represented 46 friend controls and 54 family controls.
An additional limitation is that our study focused on a single P-tau epitope (P-Thr231). It 
will be important to examine other major P-tau epitopes. Follow-up studies should seek to 
examine the time course of the plasma or serum levels of P-tau vs T-tau in the same patients 
in a larger longitudinal cohort study.
Conclusions
Acute T-tau and P-tau level elevations occur not only in severe/moderate TBI, but also in 
patients with mTBI. We also identified the P-tau–T-tau ratio as an excellent biomarker index 
for TBI. We found that both acute P-tau levels and P-tau–T-tau ratio outperformed T-tau 
levels in discriminating by severity, CT abnormality, and outcome category. Finally, we 
report, for what we believe to be the first time, plasma P-tau level and P-tau–T-tau ratio 
elevations among patients with chronic TBI. Taken together, P-tau levels and P-tau–T-tau 
ratio might be useful biomarkers for both acute and chronic TBI.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key Points
Question
What is the association between plasma phospho-tau and total-tau levels and traumatic 
brain injury presence, severity, type of pathoanatomic lesions, and patient outcome?
Findings
In a cohort study, plasma samples from the TRACK-TBI pilot study were collected at a 
single time point from 196 patients with acute traumatic brain injury and 21 patients with 
severe traumatic brain injury admitted to receive inpatient rehabilitation. Plasma 
phospho-tau levels and phospho tau–total tau ratio during the acute phase and chronic 
traumatic brain injury were superior to total-tau levels for discriminating the severity and 
status of neurotrauma patients from healthy controls.
Meaning
Plasma phospho-tau levels and phospho tau–total tau ratio might be useful diagnostic and 
prognostic biomarkers for both acute and chronic traumatic brain injury.
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Figure 1. Comparison of Plasma Total-Tau (T-tau) Level, Phospho-Tau (P-tau) Level, and P-tau–
T-tau Ratio in Patients With Acute Traumatic Brain Injury (TBI) With Different Severity and 
Healthy Controls
A, T-tau level, P-tau level, and P-tau–T-tau ratio in plasma of patients with TBI of different 
severity (Glasgow Coma Scale [GCS] score: mild, 13–15 [n = 160]; moderate, 9–12 [n = 6]; 
and severe, 3–8 [n = 12]) vs healthy control plasma (n = 20). Median and first and third 
quartiles are shown (black bars). Statistical significance was based on Kruskal-Wallis test 
comparison. Mann-Whitney test multiple group comparison results are given in eTable 2 in 
the Supplement. B, Receiver operating characteristic (ROC) curve of plasma T-tau level, P-
tau level, and P-tau–T-tau ratio for all acute TBI (n = 195) vs control (n = 20) samples. C, 
ROC of T-tau level, P-tau level, and P-tau–T-tau ratio of all patients with acute mild TBI (n 
= 162) vs controls (n = 20). D, ROC curve of acute plasma T-tau level, P-tau level, and P-
tau–T-tau ratio in distinguishing patients with TBI with GCS scores of 13 to 15 vs those with 
GCS scores of 12 or lower. Detailed characterization analysis of ROC curves is available in 
eTables 3 and 4 in the Supplement.
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Figure 2. Comparison of Plasma Total-Tau (T-tau) Level, Phospho-Tau (P-tau) Level, and P-tau–
T-tau Ratio in Acute Traumatic Brain Injury With Abnormal Cranial Computed Tomography 
(CT) (CT+) vs Normal Cranial CT (CT−)
T-tau level (A), P-tau level (B), and P-tau–T-tau ratio (C) for CT− (n = 105) and CT+ (n = 
91) patients. Median and first and third quartiles are shown (black bars). The receiver 
operating characteristic (ROC) curve is for T-tau level, P-tau level, and P-tau–T-tau ratio in 
distinguishing CT+ vs CT− (D). eTable 5 in the Supplement provides detailed 
characterization. Error bars indicate SE. P values based on Mann-Whitney test comparison.
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Figure 3. Plasma Total-Tau (T-tau) Level, Phospho-Tau (P-tau) Level, and P-tau–T-tau Ratio in 
Acute Traumatic Brain Injury in Predicting Patient Outcomes at 6 Months
T-tau level (A), P-tau level (B), and P-tau–T-tau ratio, Glascow Outcome Scale-Extended 
(GOS-E) of 7 to 8 (good outcome) vs GOS-E of 6 or lower (poor outcome). Median and first 
and third quartiles are shown (black bars). Statistical significance was based on Mann-
Whitney test comparison. Receiver operating characteristic (ROC) curves for T-tau level, P-
tau level, and P-tau–T-tau ratio in distinguishing ROC curves for good outcome GOS-E of 7 
to 8 vs GOS-E of 6 or lower (D), and ROC curves for poor outcome GOS-E of 4 or lower vs 
GOS-E of 5 to 8 (E). eTable 6 in the Supplement provides detailed analysis.
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Figure 4. Comparison of Plasma Phospho-Tau (P-tau) Level, Total-Tau (T-tau) Level, and P-tau–
T-tau Ratio in Patients With Chronic Traumatic Brain Injury (TBI) vs Healthy Controls
A, T-tau level, P-tau, and P-tau–T-tau ratio. Median and first and third quartiles are shown 
(black bars). Statistical significance was based on Mann-Whitney test comparison; for the 2 
subgroups (control vs chronic TBI), T-tau level (P = .02), P-tau level (P < .001), and P-tau–
T-tau ratio (P < .001) are significantly different. B, Receiver operating characteristic (ROC) 
curve of plasma T-tau level, P-tau level, and P-tau–T-tau ratio for patients with chronic TBI 
vs healthy controls. eTable 7 in the Supplement provides detailed ROC analysis.
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Table
Demographics and Injury Characteristics of TRACK-TBI Pilot Subjects
Characteristic Control (n = 20)
TBI
Acute (n = 196) Chronic (n = 21)
Age, mean (SD) [range], y 40.5 (14.2) [22–61] 42.4 (17.8) [16–86] 44.4 (20.5) [19–81]
Sex, No. (%)
 Male 14 (70.0) 145 (74.0) 16 (76.2)
 Female 6 (30.0) 51 (26.0) 5 (23.8)
Race, No. (%)
 White 15 (75.0) 164 (83.7) 19 (90.5)
 African American or African 3 (15.0) 18 (9.2) 1 (4.8)
 Asian 1 (5.0) 4 (2.0) 1 (4.8)
 Hawaiian or Pacific Islander 0 1 (0.5) 0
 American Indian or Alaskan Native 0 1 (0.5) 0
 ≥1 Race 1 (5.0) 8 (4.1) 0
Ethnicity, No. (%)
 Hispanic 3 (15.0) 27 (13.8) 5 (23.8)
 Non-Hispanic 17 (85.0) 167 (85.2) 12 (57.1)
 Unknown 0 2 (1.0) 4 (19.0)
Highest academic degree, No. (%)
 Below high school 26 (13.3) 1 (4.8)
 High school or GED 108 (55.1) 12 (57.1)
 College 32 (16.3) 5 (23.8)
 Graduate school 18 (9.2) 2 (10.0)
 Unknown 20 (100) 12 (6.1) 1 (4.8)
Employment, No. (%)
 Full-time 78 (39.8) 11 (52.4)
 Part-time 33 (16.8) 3 (14.3)
 Retired, student, or disabled 32 (16.3) 6 (28.6)
 Unemployed 42 (21.4) 1 (4.8)
 Unknown 20 (100) 11 (5.6) 0
Marriage status, No. (%)
 Single, never married 94 (48.0) 11 (52.4)
 Married 75 (38.3) 7 (33.3)
 Separated or divorced 14 (7.1) 0
 Widowed 6 (3.1) 3 (14.3)
 Unknown 20 (100) 7 (3.6) 0
GCS score, No. (%) NA NAa
 3–8 12 (6.1)
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Characteristic Control (n = 20)
TBI
Acute (n = 196) Chronic (n = 21)
 9–12 6 (3.1)
 13–15 160 (81.6)
 Unknown 18 (9.2)
Admission cranial CT, No. (%)b NA
 Normal 108 (55.1) 0
 Abnormal 88 (44.9) 11 (52.4)
 Unknown 0 10 (47.6)
 Negative 108 (55.1) NA
 Extra-axial only 22 (11.2) 5 (23.8)
 Intra-axial only 24 (12.2) 3 (14.3)
 Extra-axial and intra-axial 42 (21.4) 3 (14.3)
 Unknown 0 10 (47.6)
Marshall CT scale, No. (%)b NA
 1 96 (49.0) 0
 2 78 (39.8) 2 (20.0)
 3 8 (4.1) 3 (30.0)
 4 1 (0.5) 0
 5 12 (6.1) 5 (50.0)
 6 1 (0.5) 0
Outcome [6 mo], No. (%)c NA
 GOS-E
  1 7 (5.2) 0
  2 1 (0.7) 0
  3 10 (7.5) 1 (5.9)
  4 2 (1.5) 5 (29.4)
  5 13 (9.7) 5 (29.4)
  6 21 (15.7) 1 (5.9)
  7 38 (28.4) 1 (5.9)
  8 43 (32.1) 4 (23.5)
 Sample collection time postinjury, mean (SD) [range] NA 10.6 (6.4) [0.5–23.4], h 176.4 (44.5) [16.0–249.6], d
Abbreviations: CT, computed tomographic; GCS, Glasgow Coma Scale; GED, general educational development (GED Testing Service); GOS-E, 
Glasgow Outcome Scale–Extended; TBI, traumatic brain injury.
aGCS data were unavailable for all patients with chronic TBI.
bAdmission cranial CT data were not available for 11 of 21 patients with chronic TBI.
c
Data were available for 137 patients with acute TBI and 17 of those with chronic TBI.
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